Hypertension
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: men; aged between 30 and 65 years; hypertensives receiving anti-hypertensive drugs for 4 or more months; neither receiving beta-blockers nor non-dihydropyridine calcium channel blockers; neither chronotype type; inactive or insufficiently active; available to participate in the interventions at both proposed times of day (morning and evening).
Exclusion criteria
Exclusion criteria: Presence of cardiovascular diseases beyond hypertesion; presence of osteomioarticular problems that unavaiable to pratice exercise; systolic and diastolic blood pressures higher than 160 and 105 mmHg, respectively; obesity level 2 or above; presence of diabetes with complications or receiving insulin; presence of organ-target damage; presence of complex arrhythmias and/or ischemia during exercise.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure decrease verified by auscultatory technique with a minimal reduction of 4 mmHg between initial and after assessments. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep quality increase assessed by Pittsburgh Sleep Quality Index and Epworth Scale with a minimal reduction of 0,47 e 1,20 respectively between the beginning and end of the study; heart rate decrease assessed by electrocardiogram with a minimal reduction of 4 bpm between the beginning and end of the study; systemic vascular resistance decrease based on calculus considering cardiac output assessed by CO2 rebreathing technique with a minimal reduction of 7% between the beginning and end of the study; stroke volume increase calculated by quotient between cardiac output and heart rate with a minimal increase of 15% between the beginning and end of the study; improve of cardiac and vasomotor autonomic modulation verified by the increase of heart rate modulation and decrease of blood pressure modulation assessed by spectral analysis technique; plasmatic angiotensin II decrease assessed by technique of HPLC with a minimal decrease of 0,04 nmol/ml between the beginning and end of the study; plasmatic angiotensin 1-7 increase assessed by technique of HPLC with a minimal decrease of 0,05 nmol/ml between the beginning and end of the study; plasmatic vasopressin increase assessed by technique of HPLC with a minimal decrease of 0,11 nmol/ml between the beginning and end of the study; urinary 6-sulfatoxymelatonin increase assessed by technique of ELISA with a minimal increase of 6,5% between the beginning and end of the study. | — |
Countries
Brazil
Contacts
Escola de Educação Física e Esporte da Universidade de São Paulo